Diagnostic Approach to EGPA
There are no validated diagnostic criteria for EGPA—diagnosis must be based on highly suggestive clinical features, objective evidence of vasculitis (ideally from histology), ANCA testing, and eosinophilia, while classification criteria should NOT be used as diagnostic tools. 1
Critical Distinction: Classification vs. Diagnosis
The 2023 Nature Reviews Rheumatology guideline explicitly states that classification criteria (including the 1990 ACR criteria and 2022 ACR-EULAR criteria) have established sensitivity and specificity but should NOT be used as diagnostic criteria, as they were not developed for this purpose. 1 This is a common pitfall—clinicians often misuse classification criteria to diagnose individual patients, which is inappropriate.
Core Diagnostic Elements
The diagnosis of EGPA requires integration of three key components:
1. Highly Suggestive Clinical Features
Look for this specific constellation 1:
Asthma (present in >90% of patients)
- Adult-onset
- Lacks seasonal pattern
- Progressive worsening over time
Eosinophilia (>10% or >1,500 cells/μL)
- Present in almost all patients
- Caveat: Can be masked by systemic glucocorticoids 1
ENT manifestations (60-80% of patients)
- Chronic rhinosinusitis with nasal polyps
- Recurrent polyps after surgical excision
- Otitis media
Vasculitic/organ involvement features:
- Peripheral neuropathy (50-70%): mononeuritis multiplex pattern, sensory ± motor deficits, axonal damage on nerve conduction studies
- Lung infiltrates (40-50%): multiple, migratory, glucocorticoid-responsive
- Skin lesions: palpable purpura (most vasculitis-specific)
- Cardiac involvement: myocarditis, pericarditis
- Renal disease: proteinuria, hematuria, kidney failure
- Gastrointestinal involvement
- Constitutional symptoms: fatigue, weight loss, myalgia, arthralgia
2. Objective Evidence of Vasculitis
Biopsy is recommended when feasible but is NOT essential for diagnosis. 1 When obtained, look for:
- Eosinophilic vasculitis
- Perivascular eosinophilic infiltration
- Eosinophil-rich granulomatous inflammation
- Extravascular eosinophils
3. ANCA Testing
- Present in ~40% of EGPA cases 1
- Usually MPO-ANCA (not PR3-ANCA)
- ANCA-positive patients: More vasculitic features (glomerulonephritis, peripheral neuropathy, purpura)
- ANCA-negative patients: More eosinophilic features (cardiac involvement, gastroenteritis)
Baseline Diagnostic Workup
All patients with suspected EGPA require multidisciplinary evaluation including: 1
- Complete blood count with differential (eosinophil count)
- ANCA testing (MPO-ANCA and PR3-ANCA)
- Comprehensive metabolic panel
- Urinalysis (proteinuria, hematuria)
- Chest imaging
- Cardiac evaluation (ECG, troponin, consider echocardiography/cardiac MRI)
- Nerve conduction studies if neuropathy suspected
- Sinus imaging if ENT symptoms present
- Tissue biopsy when accessible and safe
Understanding Available Criteria Sets (For Context Only)
While these should NOT be used diagnostically, understanding them provides clinical context:
2022 ACR-EULAR Classification Criteria (most recent) 1, 2:
- Weighted scoring system requiring ≥6 points
- Positive factors: eosinophil count ≥1×10⁹/L (+5), obstructive airway disease (+3), nasal polyps (+3), extravascular eosinophilic inflammation (+2), mononeuritis multiplex (+1)
- Negative factors: C-ANCA/PR3-ANCA positivity (−3), hematuria (−1)
- 85% sensitivity, 99% specificity for classification among vasculitides
1990 ACR Criteria 1:
- Six items: asthma, eosinophilia >10%, neuropathy, non-fixed lung infiltrates, paranasal sinus abnormalities, histological evidence of extravascular eosinophils
- ≥4 of 6 criteria: 85% sensitivity, 99.7% specificity for classification
Key Clinical Pitfalls
Do not wait for all "classic" features—EGPA phases often overlap and don't follow a predictable sequence 1
Do not rule out EGPA based on negative ANCA—60% of patients are ANCA-negative 1
Do not dismiss the diagnosis if biopsy is unavailable—highly suggestive clinical features are sufficient 1
Check eosinophil count BEFORE starting glucocorticoids—treatment rapidly suppresses eosinophilia 1
Distinguish EGPA from other eosinophilic disorders—requires comprehensive evaluation of vasculitic features, not just eosinophilia 3
Differential Diagnosis Considerations
Must exclude:
- Other ANCA-associated vasculitides (granulomatosis with polyangiitis, microscopic polyangiitis)
- Hypereosinophilic syndromes
- Parasitic infections
- Drug-induced eosinophilia
- Eosinophilic asthma without vasculitis
- Other systemic vasculitides